Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.

NCT04250922 is registered in ClinicalTrials.gov with Laminar Pharmaceuticals as lead sponsor.

NCT NCT04250922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Lead sponsor
Laminar Pharmaceuticals
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 1, 2019
Completion date
November 30, 2026
Enrollment
144 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, primary glioblastoma